HIVE DIGITAL TECHNOLOGIES LT (HIVE.CA) Fundamental Analysis & Valuation

TSX-V:HIVE • CA4339211035

2.86 CAD
-0.02 (-0.69%)
Last: Mar 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This HIVE.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to HIVE. HIVE was compared to 68 industry peers in the Software industry. While HIVE seems to be doing ok healthwise, there are quite some concerns on its profitability. HIVE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. HIVE.CA Profitability Analysis

1.1 Basic Checks

  • In the past year HIVE has reported negative net income.
  • HIVE had a positive operating cash flow in the past year.
  • In multiple years HIVE reported negative net income over the last 5 years.
  • HIVE had a positive operating cash flow in each of the past 5 years.
HIVE.CA Yearly Net Income VS EBIT VS OCF VS FCFHIVE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • HIVE has a Return On Assets of -11.53%. This is comparable to the rest of the industry: HIVE outperforms 42.65% of its industry peers.
  • HIVE has a Return On Equity (-12.87%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -11.53%
ROE -12.87%
ROIC N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
HIVE.CA Yearly ROA, ROE, ROICHIVE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HIVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIVE.CA Yearly Profit, Operating, Gross MarginsHIVE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. HIVE.CA Health Analysis

2.1 Basic Checks

  • HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • HIVE has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, HIVE has more shares outstanding
  • Compared to 1 year ago, HIVE has an improved debt to assets ratio.
HIVE.CA Yearly Shares OutstandingHIVE.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HIVE.CA Yearly Total Debt VS Total AssetsHIVE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 4.20 indicates that HIVE is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.20, HIVE is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
  • HIVE has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • HIVE has a Debt to Equity ratio of 0.03. This is in the better half of the industry: HIVE outperforms 76.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 4.2
ROIC/WACCN/A
WACC10.08%
HIVE.CA Yearly LT Debt VS Equity VS FCFHIVE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.74 indicates that HIVE should not have too much problems paying its short term obligations.
  • With a decent Current ratio value of 1.74, HIVE is doing good in the industry, outperforming 67.65% of the companies in the same industry.
  • HIVE has a Quick Ratio of 1.74. This is a normal value and indicates that HIVE is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.74, HIVE is in the better half of the industry, outperforming 67.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74
HIVE.CA Yearly Current Assets VS Current LiabilitesHIVE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. HIVE.CA Growth Analysis

3.1 Past

  • HIVE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -763.33%.
  • The Revenue has grown by 112.51% in the past year. This is a very strong growth!
  • Measured over the past years, HIVE shows a very strong growth in Revenue. The Revenue has been growing by 31.59% on average per year.
EPS 1Y (TTM)-763.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3800%
Revenue 1Y (TTM)112.51%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%218.56%

3.2 Future

  • Based on estimates for the next years, HIVE will show a very negative growth in Earnings Per Share. The EPS will decrease by -309.31% on average per year.
  • The Revenue is expected to grow by 73.55% on average over the next years. This is a very strong growth
EPS Next Y-2185.79%
EPS Next 2Y-385.82%
EPS Next 3Y-309.31%
EPS Next 5YN/A
Revenue Next Year166.46%
Revenue Next 2Y92.76%
Revenue Next 3Y73.55%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HIVE.CA Yearly Revenue VS EstimatesHIVE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
HIVE.CA Yearly EPS VS EstimatesHIVE.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. HIVE.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HIVE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HIVE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HIVE.CA Price Earnings VS Forward Price EarningsHIVE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HIVE indicates a somewhat cheap valuation: HIVE is cheaper than 73.53% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.14
HIVE.CA Per share dataHIVE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • HIVE's earnings are expected to decrease with -309.31% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-385.82%
EPS Next 3Y-309.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HIVE.CA Dividend Analysis

5.1 Amount

  • HIVE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HIVE.CA Fundamentals: All Metrics, Ratios and Statistics

HIVE DIGITAL TECHNOLOGIES LT

TSX-V:HIVE (3/12/2026, 7:00:00 PM)

2.86

-0.02 (-0.69%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-15
Earnings (Next)06-24
Inst Owners33.02%
Inst Owner ChangeN/A
Ins Owners0.43%
Ins Owner ChangeN/A
Market Cap726.41M
Revenue(TTM)257.14M
Net Income(TTM)-71.97M
Analysts80
Price Target6.5 (127.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-254.08%
Min EPS beat(2)-423.34%
Max EPS beat(2)-84.82%
EPS beat(4)2
Avg EPS beat(4)-34.38%
Min EPS beat(4)-423.34%
Max EPS beat(4)269.73%
EPS beat(8)6
Avg EPS beat(8)19.63%
EPS beat(12)8
Avg EPS beat(12)17.68%
EPS beat(16)9
Avg EPS beat(16)-129.51%
Revenue beat(2)1
Avg Revenue beat(2)5.59%
Min Revenue beat(2)-5.73%
Max Revenue beat(2)16.9%
Revenue beat(4)2
Avg Revenue beat(4)3.24%
Min Revenue beat(4)-5.73%
Max Revenue beat(4)16.9%
Revenue beat(8)5
Avg Revenue beat(8)4.17%
Revenue beat(12)8
Avg Revenue beat(12)4.05%
Revenue beat(16)11
Avg Revenue beat(16)14.48%
PT rev (1m)-28.17%
PT rev (3m)-28.17%
EPS NQ rev (1m)-193.75%
EPS NQ rev (3m)-125.61%
EPS NY rev (1m)-537.04%
EPS NY rev (3m)-303.11%
Revenue NQ rev (1m)-20.98%
Revenue NQ rev (3m)-18.23%
Revenue NY rev (1m)-5.65%
Revenue NY rev (3m)-5.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.08
P/FCF N/A
P/OCF 6.22
P/B 0.95
P/tB 0.95
EV/EBITDA 9.14
EPS(TTM)-0.35
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)0.46
OCFY16.07%
SpS1.38
BVpS3
TBVpS3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.53%
ROE -12.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.3
Cap/Depr 140.42%
Cap/Sales 72.89%
Interest Coverage N/A
Cash Conversion 183.62%
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z 4.2
F-Score5
WACC10.08%
ROIC/WACCN/A
Cap/Depr(3y)97.27%
Cap/Depr(5y)157.57%
Cap/Sales(3y)54.64%
Cap/Sales(5y)58.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-763.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3800%
EPS Next Y-2185.79%
EPS Next 2Y-385.82%
EPS Next 3Y-309.31%
EPS Next 5YN/A
Revenue 1Y (TTM)112.51%
Revenue growth 3Y-18.07%
Revenue growth 5Y31.59%
Sales Q2Q%218.56%
Revenue Next Year166.46%
Revenue Next 2Y92.76%
Revenue Next 3Y73.55%
Revenue Next 5YN/A
EBIT growth 1Y-67.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year253.98%
EBIT Next 3Y75.31%
EBIT Next 5YN/A
FCF growth 1Y-516.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y174.74%
OCF growth 3Y-36.92%
OCF growth 5Y84.91%

HIVE DIGITAL TECHNOLOGIES LT / HIVE.CA FAQ

Can you provide the ChartMill fundamental rating for HIVE DIGITAL TECHNOLOGIES LT?

ChartMill assigns a fundamental rating of 3 / 10 to HIVE.CA.


Can you provide the valuation status for HIVE DIGITAL TECHNOLOGIES LT?

ChartMill assigns a valuation rating of 1 / 10 to HIVE DIGITAL TECHNOLOGIES LT (HIVE.CA). This can be considered as Overvalued.


Can you provide the profitability details for HIVE DIGITAL TECHNOLOGIES LT?

HIVE DIGITAL TECHNOLOGIES LT (HIVE.CA) has a profitability rating of 2 / 10.


What is the earnings growth outlook for HIVE DIGITAL TECHNOLOGIES LT?

The Earnings per Share (EPS) of HIVE DIGITAL TECHNOLOGIES LT (HIVE.CA) is expected to decline by -2185.79% in the next year.